Skip to main content

Table 1 Patient characteristics before and after cladribine treatment

From: Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis

  WHO functional class 6-MWD (m) FVC (l) ΔFVC (ml) FEV1 (l) ΔFEV1 (ml) FEV1/FVC (%) DLco (%) PaO2 (mmHg)
Cladribine Pre Post Pre Post Pre Post   Pre Post   Pre Post Pre Post Pre Post
Patient 1 M, 45 y IV III 60 220 2.67 (56%) 2.93 (62%) +260 1.00 (28%) 1.15 (32%) +150 38 37 15 16 60 (3 l) 65 (2 l)
Patient 2 F, 37 y II 0 NA NA 2.54 (66%) 3.54 (95%) +1,000 1.98 (61%) 2.90 (90%) +920 95 82 58 NA NA NA
Patient 2 F, 37 y relapse II 0 NA NA 3.33 (87%) 4.0 (110%) +670 2.43 (75%) 3.10 (95%) +670 72 79 52 70 NA NA
Patient 3 F, 55 y II-III I NA NA 2.88 (112%) 3.30 (126%) +420 1.96 (89%) 2.30 (104%) +340 69 71 67 62 82.5 NA
Patient 4 M, 50 y II II 495 NA 4.30 (98%) 4.43 (101%) +130 1.40 (41%) 1.61 (47%) +210 32 36 66 68 79.5 91.5
Patient 5 F, 40 y II-III II-III 267 282 2.6 (78%) 2.6 (79%) +0 0.8 (29%) 0.9 (31%) +100 29 18 30 28 82.5 84
  1. NA: not available; 6-MWD: 6-minute walk distance; DLco: diffusing capacity of carbon monoxide, FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; Δ: variation of FVC and FEV1 before and after cladribine treatment; PaO2: pulmonary arterial tension in blood gases, WHO: World Health Organization.
  2. Results were obtained within hours or days before the first course of cladribine therapy (“Pre”), then 1 month (up to 3 months) after the last cladribine dose (“Post”). Volumes are indicated after inhalation of short-acting bronchodilators.